RedHill Biopharma CEO and leadership

Dror has extensive managerial and transactional expertise, He was previously with ProSeed Capital, a European corporate finance boutique. Dror is a graduate of the University of Oxford (M.Jur.) and completed LL.M. studies at Harvard University. At Harvard, Dror was also a Fulbright Scholar focusing on the pharmaceutical industry and markets, an Olin Fellow for Law, Economics and Business, and an Economics Teaching Fellow at Harvard’s Economics Department. Dror received an LL.B. with distinction (First Class Honours) from the University of Leicester.

Guy Goldberg is a Chief Business Officer at RedHill Biopharma Ltd.

Over 20 years of experience in various global finance positions in several multinational corporations in High Tech and Life Science.

Driving mega global financial transactions and commercial negotiations in the international markets.

Lead companies through critical turn-around situations, strategic planning, organizational restructuring, various debt and equity financing, re-positioning, bank syndication lending, ERP implementations, cross organization cost reductions and IR activities.

Lead M&A and IPO processes.

With more than 25 years of experience in the pharmaceutical industry, Mr. Scruggs brings extensive knowledge in commercial operations and business development. He most recently served as executive vice president of business development at Salix Pharmaceuticals, Inc. (“Salix”), until its acquisition by Valeant Pharmaceuticals International, Inc. (now Bausch Health Companies Inc.). Mr. Scruggs joined Salix in 2000, after working at Oclassen Pharmaceuticals, Inc. and Watson Pharmaceuticals, Inc. At Salix, Mr. Scruggs helped build the company’s commercial organization, serving in various sales and commercial trade-related positions. He was appointed executive vice president in 2011 and was responsible for all business development activities as well as the worldwide distribution of Salix’s innovative products and intellectual property. Mr. Scruggs also served as chairperson of the board of directors of Oceana Therapeutics, Salix’s European subsidiary.

Adi Frish is a Chief Corporate & Business Development Officer at RedHill Biopharma Ltd and Director:Business Development at Medigus. He has worked as Senior VP:Business Development & Licensing at RedHill Biopharma Ltd. Adi attended UNIVERSITY OF ESSEX and Bar-Ilan University.

Gilead Raday is a Chief Operating Officer at RedHill Biopharma Ltd, Board Member at Akari Therapeutics PLC, and Managing Director at Charles Street Securities Europe LLP. He has worked as Interim CEO at SEPAL PHARMA LTD. Gilead studied at Hebrew University of Jerusalem and University of Cambridge.

Dror has extensive managerial and transactional expertise, He was previously with ProSeed Capital, a European corporate finance boutique. Dror is a graduate of the University of Oxford (M.Jur.) and completed LL.M. studies at Harvard University. At Harvard, Dror was also a Fulbright Scholar focusing on the pharmaceutical industry and markets, an Olin Fellow for Law, Economics and Business, and an Economics Teaching Fellow at Harvard’s Economics Department. Dror received an LL.B. with distinction (First Class Honours) from the University of Leicester.

With more than 25 years of experience in the pharmaceutical industry, Mr. Scruggs brings extensive knowledge in commercial operations and business development. He most recently served as executive vice president of business development at Salix Pharmaceuticals, Inc. (“Salix”), until its acquisition by Valeant Pharmaceuticals International, Inc. (now Bausch Health Companies Inc.). Mr. Scruggs joined Salix in 2000, after working at Oclassen Pharmaceuticals, Inc. and Watson Pharmaceuticals, Inc. At Salix, Mr. Scruggs helped build the company’s commercial organization, serving in various sales and commercial trade-related positions. He was appointed executive vice president in 2011 and was responsible for all business development activities as well as the worldwide distribution of Salix’s innovative products and intellectual property. Mr. Scruggs also served as chairperson of the board of directors of Oceana Therapeutics, Salix’s European subsidiary.